Netflix partners with SoftBank for Japanese launch
Aug 25, 2015
Netflix is rising in the Land of the Rising Sun. When the online streaming service launches in Japan on Sept. 2., mobile provider SoftBank will exclusively offer a fully integrated Netflix experience
Zacks By Zacks Equity Research
1 hour ago
Estimates for SGYP have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks
By Jim Cramer
Jul 20, 2015 | 01:00 AM EDT
I am making a case for $150 for Netflix, it's the opportunity -- the total addressable market is just too great and just getting started.
The Fly On the Wall
Breaking News Feed
Netflix Earns Buy Rating from Goldman Sachs (NFLX). July 19th, 2015
Goldman Sachs ( NFLX ) has plenty of room to run.
Hot growth stock ( FIT )
By Jeff Reeves
Fitbit is a fast-growing stock that is a dominant name in the rapidly expanding realm of fitness wearables. Fitbit has powerful momentum — and most importantly, solid profits. The deck seems stacked for blowout earnings surprises as Fitbit continues to maintain its strong brandi n the wearables space. Fitbit remains the gold standard with its huge brand recogntion, the tailwind of organic growth in wearables, and robust profit margins
Piper Bullish on Fitbit Into First Earnings Report
The Fly Staff
Ambarella Earnings Accelerate Further With Drone Growth Seen Adding Boost
CyberArk Files For Secondary Offering After Strong Q1
BY GILLIAN RICH, INVESTOR'S BUSINESS DAILY
6-8-15 08:54 AM ET
CyberArk Software (NASDAQ:CYBR) said Friday it filed for a follow-on stock offering.
The cybersecurity company filed a registration statement with the Securities and Exchange Commission for the secondary offering. The majority of the shares will be sold by current shareholders with $50 million in shares to be sold by CyberArk. The total number of shares to be sold hasn't been decided yet.
Esperion Therapeutics (ESPR) Weakness Overdone Amid FDA AdCom on SNY/REGN's Praluent, UBS UBS analyst Andrew Peters maintained a Buy rating and price target of $140 on Esperion Therapeutics (NASDAQ: ESPR)